A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q-syndrome

Nature Medicine

Volumn 16, Issue 1, 2010, Pages 59-66

  Barlow, Jillian L ^a   Drynan, Lesley F ^a   Hewett, Duncan R ^a   Holmes, Luke R ^a   Lorenzo Abalde, Silvia ^a   Lane, Alison L ^a   Jolin, Helen E ^a   Pannell, Richard ^a   Middleton, Angela J ^a   Wong, See Heng ^a   Warren, Alan J ^a,c   Wainscoat, James S ^b   Boultwood, Jacqueline ^b   McKenzie, Andrew N J ^a  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; RIBOSOMAL PROTEIN S14; RIBOSOME PROTEIN; UNCLASSIFIED DRUG;

5Q SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW; CHROMOSOME 5Q; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CONTROLLED STUDY; ERYTHROID CELL; HEMATOPOIETIC STEM CELL; HUMAN; MACROCYTIC ANEMIA; MEGAKARYOCYTE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL; TUMOR SUPPRESSOR GENE;

ANEMIA, MACROCYTIC; ANIMALS; APOPTOSIS; CHROMOSOME DELETION; CHROMOSOMES, MAMMALIAN; DISEASE MODELS, ANIMAL; GENES, P53; HEMATOPOIETIC STEM CELLS; HUMANS; MICE; MYELODYSPLASTIC SYNDROMES; SYNTENY;

MUS;

EID: 73849128091     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2063     Document Type: Article

References (49)

1. Van den Berghe, H. et al. Distinct hematological disorder with deletion of long arm of no.5 chromosome. Nature 251, 437-438 (1974).
2. Giagounidis, A.A., Germing, U., Wainscoat, J.S., Boultwood, J. & Aul, C. The 5q-syndrome. Hematology 9, 271-277 (2004).
3. List, A. et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N. Engl. J. Med. 355, 1456-1465 (2006).
4. Vardiman, J.W., Harris, N.L. & Brunning, R.D. The World Health Organization (WHO) classifcation of the myeloid neoplasms. Blood 100, 2292-2302 (2002).
5. Boultwood, J., Lewis, S. & Wainscoat, J.S. The 5q-syndrome. Blood 84, 3253-3260 (1994).
6. Le Beau, M.M. et al. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proc. Natl. Acad. Sci. USA 90, 5484-5488 (1993).
7. Boultwood, J. et al. Molecular mapping of uncharacteristically small 5q deletions in two patients with the 5q-syndrome: delineation of the critical region on 5q and identifcation of a 5q-breakpoint. Genomics 19, 425-432 (1994).
8. Boultwood, J. et al. Narrowing and genomic annotation of the commonly deleted region of the 5q-syndrome. Blood 99, 4638-4641 (2002).
9. Lai, F. et al. Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q). Genomics 71, 235-245 (2001).
10. Boultwood, J. et al. Gene expression profling of CD34+ cells in patients with the 5q-syndrome. Br. J. Haematol. 139, 578-589 (2007).
11. Soengas, M.S. et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409, 207-211 (2001).
12. Teitz, T. et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplifcation of MYCN. Nat. Med. 6, 529-535 (2000).
13. Brekken, R.A. & Sage, E.H. SPARC, a matricellular protein: at the crossroads of cell-matrix. Matrix Biol. 19, 569-580 (2000).
14. Lehmann, S. et al. Common deleted genes in the 5q-syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null mice. Leukemia 21, 1931-1936 (2007).
15. Ebert, B.L. et al. Identifcation of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature 451, 335-339 (2008).
16. Draptchinskaia, N. et al. The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anemia. Nat. Genet. 21, 169-175 (1999).
17. Bagchi, A. et al. CHD5 is a tumor suppressor at human 1p36. Cell 128, 459-475 (2007).
18. Zhu, Y. et al. Genomic interval engineering of mice identifes a novel modulator of triglyceride production. Proc. Natl. Acad. Sci. USA 97, 1137-1142 (2000).
19. LePage, D.F., Church, D.M., Millie, E., Hassold, T.J. & Conlon, R.A. Rapid generation of nested chromosomal deletions on mouse chromosome 2. Proc. Natl. Acad. Sci. USA 97, 10471-10476 (2000).
20. Dixon, J., Brakebusch, C., Fassler, R. & Dixon, M.J. Increased levels of apoptosis in the prefusion neural folds underlie the craniofacial disorder, Treacher Collins syndrome. Hum. Mol. Genet. 9, 1473-1480 (2000).
21. Forster, A. et al. Engineering de novo reciprocal chromosomal translocations associated with Mll to replicate primary events of human cancer. Cancer Cell 3, 449-458 (2003).
22. Grobe, K. et al. Cerebral hypoplasia and craniofacial defects in mice lacking heparan sulfate Ndst1 gene function. Development 132, 3777-3786 (2005).
23. Bikoff, E.K. et al. Defective major histocompatibility complex class II assembly, transport, peptide acquisition and CD4+ T cell selection in mice lacking invariant chain expression. J. Exp. Med. 177, 1699-1712 (1993).
24. Jones, N.C. et al. Prevention of the neurocristopathy Treacher Collins syndrome through inhibition of p53 function. Nat. Med. 14, 125-133 (2008).
25. McGowan, K.A. et al. Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects. Nat. Genet. 40, 963-970 (2008).
26. Panic, L. et al. Ribosomal protein S6 gene haploinsuffciency is associated with activation of a p53-dependent checkpoint during gastrulation. Mol. Cell. Biol. 26, 8880-8891 (2006).
27. Warner, J.R. & McIntosh, K.B. How common are extraribosomal functions of ribosomal proteins? Mol. Cell 34, 3-11 (2009).
28. Danilova, N., Sakamoto, K.M. & Lin, S. p53 family in development. Mech. Dev. 125, 919-931 (2008).
29. Kiel, M.J. et al. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 121, 1109-1121 (2005).
30. Loonstra, A. et al. Growth inhibition and DNA damage induced by Cre recombinase in mammalian cells. Proc. Natl. Acad. Sci. USA 98, 9209-9214 (2001).
31. Pellagatti, A. et al. Haploinsuffciency of RPS14 in 5q-syndrome is associated with deregulation of ribosomal-and translation-related genes. Br. J. Haematol. 142, 57-64 (2008).
32. Ferreira-Cerca, S., Poll, G., Gleizes, P.E., Tschochner, H. & Milkereit, P. Roles of eukaryotic ribosomal proteins in maturation and transport of pre-18S rRNA and ribosome function. Mol. Cell 20, 263-275 (2005).
33. Jakovljevic, J. et al. The carboxy-terminal extension of yeast ribosomal protein S14 is necessary for maturation of 43S preribosomes. Mol. Cell 14, 331-342 (2004).
34. Dokal, I. & Vulliamy, T. Inherited aplastic anemias/bone marrow failure syndromes. Blood Rev. 22, 141-153 (2008).
35. Gazda, H.T. et al. Ribosomal protein S24 gene is mutated in Diamond-Blackfan anemia. Am. J. Hum. Genet. 79, 1110-1118 (2006).
36. Janov, A.J., Leong, T., Nathan, D.G. & Guinan, E.C. Diamond-Blackfan anemia. Natural history and sequelae of treatment. Medicine (Baltimore) 75, 77-78 (1996).
37. Menne, T.F. et al. The Shwachman-Bodian-Diamond syndrome protein mediates translational activation of ribosomes in yeast. Nat. Genet. 39, 486-495 (2007).
38. Sulic, S. et al. Inactivation of S6 ribosomal protein gene in T lymphocytes activates a p53-dependent checkpoint response. Genes Dev. 19, 3070-3082 (2005).
39. Danilova, N., Sakamoto, K.M. & Lin, S. Ribosomal protein S19 defciency in zebrafsh leads to developmental abnormalities and defective erythropoiesis through activation of p53 protein family. Blood 112, 5228-5237 (2008).
40. Valdez, B.C., Henning, D., So, R.B., Dixon, J. & Dixon, M.J. The Treacher Collins syndrome (TCOF1) gene product is involved in ribosomal DNA gene transcription by interacting with upstream binding factor. Proc. Natl. Acad. Sci. USA 101, 10709-10714 (2004).
41. Gonzales, B. et al. The Treacher Collins syndrome (TCOF1) gene product is involved in pre-rRNA methylation. Hum. Mol. Genet. 14, 2035-2043 (2005).
42. Dixon, J. et al. Tcof1/Treacle is required for neural crest cell formation and proliferation defciencies that cause craniofacial abnormalities. Proc. Natl. Acad. Sci. USA 103, 13403-13408 (2006).
43. Fumagalli, S. et al. Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction. Nat. Cell Biol. 11, 501-508 (2009).
44. Patel, S.R. et al. Differential roles of microtubule assembly and sliding in proplatelet formation by megakaryocytes. Blood 106, 4076-4085 (2005).
45. Montaville, P. et al. Nuclear translocation of the calcium-binding protein ALG-2 induced by the RNA-binding protein RBM22. Biochim. Biophys. Acta 1763, 1335-1343 (2006).
46. Venables, J.P. Aberrant and alternative splicing in cancer. Cancer Res. 64, 7647-7654 (2004).
47. Deller, T. et al. Synaptopodin-defcient mice lack a spine apparatus and show defcits in synaptic plasticity. Proc. Natl. Acad. Sci. USA 100, 10494-10499 (2003).
48. Vician, L., Silver, A.L., Farias-Eisner, R. & Herschman, H.R. NID67, a small putative membrane protein, is preferentially induced by NGF in PC12 pheochromocytoma cells. J. Neurosci. Res. 64, 108-120 (2001).
49. Donehower, L.A. et al. Mice defcient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215-221 (1992).